Flowering phenology and yield-related traits in an interspecific cross between Coffea pseudozanguebariae Bridson and C. canephora Pierre

Higher caffeine content and cup beverage bitterness considerably depreciated the commercial value of Coffea canephora Pierre (CAN) compared with C. arabica L (ARA). Wild caffeine-free species like C. pseudozanguebariae Bridson (PSE) offer the opportunity to produce new CAN varieties containing little or no caffeine. F1 plants resulting from a PSE × CAN cross, and BC1 individuals, derived from the first backcross generation (PSE × CAN) × CAN) were produced. In order to assess flowering phenology and yield traits in F1 and BC1 hybrids, six morphological characters including flowering time, pollen viability (PV), fructification rate (FR), seed set (SSET), flower number per node (NFN) and 100-bean weight (W100) were studied under environmental conditions in Côte d’Ivoire. The results showed that F1 plants flowered only in February while, for BC1, 20% and 80% of the plants flowered in January and February, respectively

Eye health and quality of life: an umbrella review protocol.

INTRODUCTION: Vision impairment and eye disease are major global health concerns and have been associated with increased morbidity and mortality, and lower quality of life. Quality of life, whether generic, vision-specific or disease-specific, is an important measure of the impact of eye health on people's daily activities, well-being and visual function, and is increasingly used to evaluate the impact of ophthalmic interventions and new devices. While many studies and reviews have examined the relationship between vision or eye health and quality of life across different contexts, there has yet to be a synthesis of the impact of vision impairment, eye disease and ophthalmic interventions on quality of life globally and across the lifespan. METHODS AND ANALYSIS: An umbrella review of systematic reviews will be conducted to address these two questions: (1) What is the association of vision impairment and eye disease with quality of life? (2) What is the impact of ophthalmic interventions on quality of life? A search of related literature will be performed on the 11 February 2020 in Medline Ovid, Embase.com, Cochrane Database of Systematic Reviews, Proquest Dissertations and Theses Global, and the grey literature, and repeated at the synthesis stage. Title/abstract and full-text screening, methodological quality assessment and data extraction will be conducted by reviewers working independently and in duplicate. Assessment of methodological quality and data extraction will be performed using Joanna Briggs Institute standard forms. Findings from the systematic reviews and their methodological quality will be summarised qualitatively in the text and using tables. ETHICS AND DISSEMINATION: No ethical approval is required. Results of this umbrella review will be published in a peer-reviewed journal and summarised in the Lancet Global Health Commission on Global Eye Health. TRIAL REGISTRATION NUMBER: This protocol was registered in the Open Science Framework Registries (https://osf.io/qhv9g/)

Efficacy of canakinumab in patients with Still's disease across different lines of biologic therapy: real-life data from the International AIDA Network Registry for Still's Disease

Introduction: The effectiveness of canakinumab may change according to the different times it is used after Still's disease onset. This study aimed to investigate whether canakinumab (CAN) shows differences in short- and long-term therapeutic outcomes, according to its use as different lines of biologic treatment.Methods: Patients included in this study were retrospectively enrolled from the AutoInflammatory Disease Alliance (AIDA) International Registry dedicated to Still's disease. Seventy-seven (51 females and 26 males) patients with Still's disease were included in the present study. In total, 39 (50.6%) patients underwent CAN as a first-line biologic agent, and the remaining 38 (49.4%) patients were treated with CAN as a second-line biologic agent or subsequent biologic agent.Results: No statistically significant differences were found between patients treated with CAN as a first-line biologic agent and those previously treated with other biologic agents in terms of the frequency of complete response (p =0.62), partial response (p =0.61), treatment failure (p >0.99), and frequency of patients discontinuing CAN due to lack or loss of efficacy (p =0.2). Of all the patients, 18 (23.4%) patients experienced disease relapse during canakinumab treatment, 9 patients were treated with canakinumab as a first-line biologic agent, and nine patients were treated with a second-line or subsequent biologic agent. No differences were found in the frequency of glucocorticoid use (p =0.34), daily glucocorticoid dosage (p =0.47), or concomitant methotrexate dosage (p =0.43) at the last assessment during CAN treatment.Conclusion: Canakinumab has proved to be effective in patients with Still's disease, regardless of its line of biologic treatment

An Organic Redox Flow Cell‐Inspired Paper‐Based Primary Battery

A portable paper‐based organic redox flow primary battery using sustainable quinone chemistry is presented. The compact prototype relies on the capillary forces of the paper matrix to develop a quasi‐steady flow of the reactants through a pair of porous carbon electrodes without the need of external pumps. Co‐laminar capillary flow allows operation Under mixed‐media conditions, in which an alkaline anolyte and an acidic catholyte are employed. This feature enables higher electrochemical cell voltages during discharge operation and the utilization of a wider range of available species and electrolytes and provides the advantage to form a neutral or near‐neutral pH as the electrolytes neutralize at the absorbent pad, which allows a safe disposal after use. The effects of the device design parameters have been studied to enhance battery features such as power output, operational time, and fuel utilization. The device achieves a faradaic efficiency of up to 98 %, which is the highest reported in a capillary‐based electrochemical power source, as well as a cell capacity of up to 11.4 Ah L−1 cm−2, comparable to state‐of‐the‐art large‐scale redox flow cells.The funding for this research provided through the Science for Solving Society's Problems Challenge by the Electrochemical Society and the Bill & Melinda Gates Foundation is highly appreciated. P.A. acknowledges support from CONACyT through a scholarship to pursue postgraduate studies. N.S. is thankful for financial support received from ERC Consolidator Grant (SUPERCELL—GA.648518). Additional support from the Natural Sciences and Engineering Research Council of Canada (NSERC), Canada Foundation for Innovation (CFI) and British Columbia Knowledge Development Fund (BCKDF) is also acknowledged. E.K. acknowledges support from the Canada Research Chairs program.Peer reviewe

A Metal-Free and Biotically Degradable Battery for Portable Single-Use Applications

This article presents a new approach for environmentally benign, low-cost batteries intended for single-use applications. The proposed battery is designed and fabricated using exclusively organic materials such as cellulose, carbon, and wax and features an integrated quinone-based redox chemistry to generate electricity within a compact form factor. This primary capillary flow battery is activated by the addition of a liquid sample and has shown continuous operation up to 100 min with an output voltage that can be conveniently scaled to match the voltage needs of portable electronic devices (1.5–3.0 V). Once depleted, the battery can be disposed of without the need for any recycling facility, as its components are nontoxic and shown to be biotically degradable in a standardized test. The practical utility of the battery is demonstrated by direct substitution of a lithium ion coin cell in a diagnostic application.info:eu-repo/semantics/publishedVersio

Eye Health and Quality of Life: An Umbrella Review Protocol

This is a protocol for an umbrella review (or systematic review of systematic reviews) that will examine the impact of vision impairment, eye disease and ophthalmic interventions on quality of life globally and across the lifespa

A Global Assessment of Eye Health and Quality of Life A Systematic Review of Systematic Reviews

IMPORTANCE: More than 1 billion people worldwide have vision impairment or blindness from potentially preventable or correctable causes. Quality of life, an important measure of physical, emotional, and social well-being, appears to be negatively associated with vision impairment, and increasingly, ophthalmic interventions are being assessed for their association with quality of life. OBJECTIVE: To examine the association between vision impairment or eye disease and quality of life, and the outcome of ophthalmic interventions on quality of life globally and across the life span, through an umbrella review or systematic review of systematic reviews. EVIDENCE REVIEW: The electronic databases MEDLINE, Ovid, Embase, Cochrane Database of Systematic Reviews, Proquest Dissertations, and Theses Global were searched from inception through June 29, 2020, using a comprehensive search strategy. Systematic reviews addressing vision impairment, eye disease, or ophthalmic interventions and quantitatively or qualitatively assessing health-related, vision-related, or disease-specific quality of life were included. Article screening, quality appraisal, and data extraction were performed by 4 reviewers working independently and in duplicate. The Joanna Briggs Institute critical appraisal and data extraction forms for umbrella reviews were used. FINDINGS: Nine systematic reviews evaluated the association between quality of life and vision impairment, age-related macular degeneration, glaucoma, diabetic retinopathy, or mendelian eye conditions (including retinitis pigmentosa). Of these, 5 were reviews of quantitative observational studies, 3 were reviews of qualitative studies, and 1 was a review of qualitative and quantitative studies. All found an association between vision impairment and lower quality of life. Sixty systematic reviews addressed at least 1 ophthalmic intervention in association with quality of life. Overall, 33 unique interventions were investigated, of which 25 were found to improve quality of life compared with baseline measurements or a group receiving no intervention. These interventions included timely cataract surgery, anti-vascular endothelial growth factor therapy for age-related macular degeneration, and macular edema. CONCLUSIONS AND RELEVANCE: There is a consistent association between vision impairment, eye diseases, and reduced quality of life. These findings support pursuing ophthalmic interventions, such as timely cataract surgery and anti-vascular endothelial growth factor therapy, for common retinal diseases, where indicated, to improve quality of life for millions of people globally each year

Orbital/ocular inflammatory involvement in VEXAS syndrome: Data from the international AIDA network VEXAS registry

VEXAS syndrome is a recently described monogenic autoinflammatory disease capable of manifesting itself with a wide array of organs and tissues involvement. Orbital/ocular inflammatory manifestations are frequently described in VEXAS patients. The objective of this study is to further describe orbital/ocular conditions in VEXAS syndrome while investigating potential associations with other disease manifestations. In the present study, twenty-seven out of 59 (45.8 %) VEXAS patients showed an inflammatory orbital/ocular involvement during their clinical history. The most frequent orbital/ocular affections were represented by periorbital edema in 8 (13.6 %) cases, episcleritis in 5 (8.5 %) patients, scleritis in 5 (8.5 %) cases, uveitis in 4 (6.8 %) cases, conjunctivitis in 4 (6.8 %) cases, blepharitis in 3 (5.1 %) cases, orbital myositis in 2 (3.4 %) cases. A diagnosis of systemic immune-mediated disease was observed in 15 (55.6 %) cases, with relapsing polychondritis diagnosed in 12 patients. A significant association was observed between relapsing polychondritis and orbital/ocular involvement in VEXAS syndrome (Relative Risk: 2.37, 95 % C.I. 1.03-5.46, p = 0.048). Six deaths were observed in the whole cohort of patients after a median disease duration of 1.2 (IQR=5.35) years, 5 (83.3 %) of which showed orbital/ocular inflammatory involvement. In conclusion, this study confirms that orbital/ocular inflammatory involvement is a common finding in VEXAS patients, especially when relapsing polychondritis is diagnosed. This makes ophthalmologists a key figure in the diagnostic process of VEXAS syndrome. The high frequency of deaths observed in this study seems to suggest that patients with orbital/ocular involvement may require increased attention and more careful follow-up